IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Spectrum Pharmaceuticals, Inc. & Encourages Inve...
September 19 2016 - 7:19PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that it is
investigating claims against Spectrum Pharmaceuticals, Inc.
(“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible
violations of federal securities laws.
If you purchased shares of Spectrum and want more information,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
The investigation focuses on a statement by Spectrum that it
failed to disclose that the Food & Drug Administration advised
it to not submit a New Drug Application for its drug candidate
apaziquone back in December of 2012.
If you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919006554/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024